Cytokinetics Inc’s filing revealed that its EVP Research & Development Malik Fady Ibraham unloaded Company’s shares for reported $0.12 million on Oct 07 ’25. In the deal valued at $60.56 per share,2,000 shares were sold. As a result of this transaction, Malik Fady Ibraham now holds 140,610 shares worth roughly $8.58 million.
Then, Kaye Edward M. MD sold 6,757 shares, generating $405,420 in total proceeds. Upon selling the shares at $60.00, the Director now owns 9,778 shares.
Before that, EDWARD KAYE bought 6,757 shares. Cytokinetics Inc shares valued at $384,946 were divested by the Director at a price of $56.97 per share.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Tuesday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock jump 2.42% to $61.03. Over the last five days, the stock has gained 1.43%. Cytokinetics Inc shares have risen nearly 14.83% since the year began. Nevertheless, the stocks have risen 29.74% over the past one year.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-09-30, growing by 0.28 million shares to a total of 14.11 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 13.83 million shares. There was a rise of 1.98%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
